Mesoporous bowl-shaped polydopamine co-loaded temozolomide and indocyanine green for synergistically inhibiting glioblastoma
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Advanced Nanomaterials in Catalysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (51)
Show source-provided references
1. Zou Y, Wang Y, Xu S, et al. Brain co-delivery of temozolomide and cisplatin for combinatorial glioblastoma chemotherapy. Adv Mater, 2022, 34: 220395810.1002/adma.202203958 ↗
2. Hsu TI, Chen YP, Zhang RL, et al. Overcoming the blood-brain tumor barrier with docetaxel-loaded mesoporous silica nanoparticles for treatment of temozolomide-resistant glioblastoma. ACS Appl Mater Interfaces, 2024, 16: 21722–2173510.1021/acsami.4c04289 ↗
3. He Q, Liu J, Liang J, et al. Towards Improvements for Penetrating the Blood-Brain Barrier—Recent Progress from a Material and Pharmaceutical Perspective. Cells, 2018, 7: 2410.3390/cells7040024 ↗
4. Anjum K, Shagufta BI, Abbas SQ, et al. Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: A review. Biomed Pharmacother, 2017, 92: 681–68910.1016/j.biopha.2017.05.125 ↗
5. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med, 2005, 352: 997–100310.1056/NEJMoa043331 ↗
6. Sekerdag E, Lüle S, Bozdağ Pehlivan S, et al. Nose-to-brain delivery of farnesylthiosalicylic acid loaded hybrid nanoparticles in the treatment of glioblastoma. J Neurol Sci, 2017, 381: 171–17210.1016/j.jns.2017.08.499 ↗
7. Minniti G, De Sanctis V, Muni R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J NeuroOncol, 2008, 88: 97–10310.1007/s11060-008-9538-0 ↗
8. Zhu L, Ren Y, Dong M, et al. Ultrasmall metal TPZ complexes with deep tumor penetration for enhancing radiofrequency ablation therapy and inducing antitumor immune responses. Small, 2024, 20: 231124410.1002/smll.202311244 ↗
9. Wu W, Klockow JL, Zhang M, et al. Glioblastoma multiforme (GBM): an overview of current therapies and mechanisms of resistance. Pharmacol Res, 2021, 171: 10578010.1016/j.phrs.2021.105780 ↗
10. Oraiopoulou ME, Tzamali E, Psycharakis SE, et al. The temozolomidedoxorubicin paradox in glioblastoma in vitro-in silico preclinical drug-screening. Sci Rep, 2024, 14: 375910.1038/s41598-024-53684-y ↗
11. Mrugala MM, Chamberlain MC. Mechanisms of disease: temozolomide and glioblastoma—look to the future. Nat Rev Clin Oncol, 2008, 5: 476–48610.1038/ncponc1155 ↗
12. Kumari S, Ahsan SM, Kumar JM, et al. Overcoming blood brain barrier with a dual purpose Temozolomide loaded Lactoferrin nanoparticles for combating glioma (SERP-17-12433). Sci Rep, 2017, 7: 660210.1038/s41598-017-06888-4 ↗
13. Mendiratta S, Hussein M, Nasser HA, et al. Multidisciplinary role of mesoporous silica nanoparticles in brain regeneration and cancers: from crossing the blood-brain barrier to treatment. Part Part Syst Charact, 2019, 36: 190019510.1002/ppsc.201900195 ↗
14. Xu B, Li S, Shi R, et al. Multifunctional mesoporous silica nanoparticles for biomedical applications. Sig Transduct Target Ther, 2023, 8: 43510.1038/s41392-023-01654-7 ↗
15. Lam FC, Morton SW, Wyckoff J, et al. Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles. Nat Commun, 2018, 9: 199110.1038/s41467-018-04315-4 ↗
16. Domingo-Lopez DA, Lattanzi G, H. J. Schreiber L, et al. Medical devices, smart drug delivery, wearables and technology for the treatment of Diabetes Mellitus. Adv Drug Deliver Rev, 2022, 185: 11428010.1016/j.addr.2022.114280 ↗
17. Elsadek NE, Nagah A, Ibrahim TM, et al. Electrospun nanofibers revisited: an update on the emerging applications in nanomedicine. Materials, 2022, 15: 193410.3390/ma15051934 ↗
18. Kolimi P, Narala S, Youssef AAA, et al. A systemic review on development of mesoporous nanoparticles as a vehicle for transdermal drug delivery. Nanotheranostics, 2023, 7: 70–8910.7150/ntno.77395 ↗
19. Wei G, Yang G, Wang Y, et al. Phototherapy-based combination strategies for bacterial infection treatment. Theranostics, 2020, 10: 12241–1226210.7150/thno.52729 ↗
20. Zhou S, Wu C, Shen P, et al. Tumor microenvironment-responsive multifunctional nanoplatform with selective toxicity for MRI-guided photothermal/photodynamic/nitric oxide combined cancer therapy. Chem Eng J, 2024, 481: 14861810.1016/j.cej.2024.148618 ↗
21. Han HS, Choi KY. Advances in nanomaterial-mediated photothermal cancer therapies: toward clinical applications. Biomedicines, 2021, 9: 30510.3390/biomedicines9030305 ↗
22. Li X, Yong T, Wei Z, et al. Reversing insufficient photothermal therapy-induced tumor relapse and metastasis by regulating cancer-associated fibroblasts. Nat Commun, 2022, 13: 279410.1038/s41467-022-30306-7 ↗
23. Zeng S, Guo Z, Hao Y, et al. Tumor-microenvironment-activatable organic phototheranostic agents for cancer therapy. Coord Chem Rev, 2024, 509: 21578610.1016/j.ccr.2024.215786 ↗
24. Yang S, Pan H, George BP, et al. Bridging the gaps in cancer photothermal therapy through the intersection of nanotechnology and cell membrane coating. Chem Eng J, 2024, 484: 14964110.1016/j.cej.2024.149641 ↗
25. Yuan X, Zhou JL, Yuan L, et al. Phototherapy: progress, challenges, and opportunities. Sci China Chem, 2025, 68: 826–86510.1007/s11426-024-2411-7 ↗
26. Lin Y, Zhou K, Zhang S, et al. Carbon-coated magnetite nanoclusters with NIR-II absorbance for imaging-guided photothermal-chemodynamic synergistic therapy. Sci China Mater, 2023, 66: 2492–250310.1007/s40843-022-2389-5 ↗
27. Pan T, Yang K, Li J, et al. Self-assembled quercetin-Fe3+ nanoparticles for synergetic near-infrared light-triggered low-temperature photothermal/glutathione-activated chemodynamic therapy. Sci China Mater, 2023, 66: 3735–374310.1007/s40843-023-2536-1 ↗
28. Wang X, Wang C, Cheng L, et al. Noble metal coated single-walled carbon nanotubes for applications in surface enhanced Raman scattering imaging and photothermal therapy. J Am Chem Soc, 2012, 134: 7414–742210.1021/ja300140c ↗
29. Liang C, Diao S, Wang C, et al. Tumor metastasis inhibition by imaging-guided photothermal therapy with single-walled carbon nanotubes. Adv Mater, 2014, 26: 5646–565210.1002/adma.201401825 ↗
30. Xia M, Wang Q, Liu Y, et al. Self-propelled assembly of nanoparticles with self-catalytic regulation for tumour-specific imaging and therapy. Nat Commun, 2024, 15: 46010.1038/s41467-024-44736-y ↗
31. Xing Y, Ding T, Wang Z, et al. Temporally controlled photothermal/photodynamic and combined therapy for overcoming multidrug resistance of cancer by polydopamine nanoclustered micelles. ACS Appl Mater Interfaces, 2019, 11: 13945–1395310.1021/acsami.9b00472 ↗
32. Farokhi M, Mottaghitalab F, Saeb MR, et al. Functionalized theranostic nanocarriers with bio-inspired polydopamine for tumor imaging and chemo-photothermal therapy. J Control Release, 2019, 309: 203–21910.1016/j.jconrel.2019.07.036 ↗
33. Wang S, Wannasarit S, Figueiredo P, et al. Intracellular delivery of budesonide and polydopamine Co-loaded in endosomolytic poly(butyl methacrylate-co-methacrylic acid) grafted acetalated dextran for macrophage phenotype switch from M1 to M2. Adv Ther, 2020, 4: 200005810.1002/adtp.202000058 ↗
34. Li F, Ma H, Luo H, et al.211At-labeled nanoscale polydopamine decorated with FAPI for synergistic targeted-alpha therapy and photothermal therapy of glioma. ACS Appl Nano Mater, 2024, 7: 6831–683810.1021/acsanm.3c05525 ↗
35. Wang Z, Wang L, Prabhakar N, et al. CaP coated mesoporous polydopamine nanoparticles with responsive membrane permeation ability for combined photothermal and siRNA therapy. Acta BioMater, 2019, 86: 416–42810.1016/j.actbio.2019.01.002 ↗
36. Zhou L, Xiang H, Liu S, et al. Folic acid functionalized AQ4N/Gd@PDA nanoplatform with real-time monitoring of hypoxia relief and enhanced synergistic chemo/photothermal therapy in glioma. IJN, 2024, Volume 19: 3367–338610.2147/IJN.S451921 ↗
37. Wang Y, Song S, Lu T, et al. Oxygen-supplementing mesoporous polydopamine nanosponges with WS2 QDs-embedded for CT/MSOT/MR imaging and thermoradiotherapy of hypoxic cancer. Biomaterials, 2019, 220: 11940510.1016/j.biomaterials.2019.119405 ↗
38. Wu D, Zhou J, Chen X, et al. Mesoporous polydopamine with built-in plasmonic core: traceable and NIR triggered delivery of functional proteins. Biomaterials, 2020, 238: 11984710.1016/j.biomaterials.2020.119847 ↗
39. Zhang L, Yang P, Guo R, et al. Multifunctional mesoporous polydopamine with hydrophobic paclitaxel for photoacoustic imaging-guided chemo-photothermal synergistic therapy. IJN, 2019, Volume 14: 8647–866310.2147/IJN.S218632 ↗
40. Bokare AD, Choi W. Review of iron-free Fenton-like systems for activating H2O2 in advanced oxidation processes. J Hazard Mater, 2014, 275: 121–13510.1016/j.jhazmat.2014.04.054 ↗
41. Chen S, Huang R, Shen F, et al. Enhancing antitumor immunity with stimulus-responsive mesoporous silicon in combination with chemotherapy and photothermal therapy. BioMater Sci, 2024, 12: 3826–384010.1039/D4BM00556B ↗
42. Kwon HJ, Cha MY, Kim D, et al. Mitochondria-targeting ceria nanoparticles as antioxidants for Alzheimer’s disease. ACS Nano, 2016, 10: 2860–287010.1021/acsnano.5b08045 ↗
43. Zhu M, Shi Y, Shan Y, et al. Recent developments in mesoporous polydopamine-derived nanoplatforms for cancer theranostics. J Nanobiotechnol, 2021, 19: 38710.1186/s12951-021-01131-9 ↗
44. Karakoti AS, Singh S, Kumar A, et al. PEGylated nanoceria as radical scavenger with tunable redox chemistry. J Am Chem Soc, 2009, 131: 14144–1414510.1021/ja9051087 ↗
45. Bai Y, Zhang B, Chen L, et al. Facile one-pot synthesis of polydopamine carbon dots for photothermal therapy. Nanoscale Res Lett, 2018, 13: 28710.1186/s11671-018-2711-2 ↗
46. Li Y, Xu H, Li H, et al. Controlled preparation and photothermal properties of polydopamine submicrospheres. InOrg Chem Commun, 2021, 124: 10839510.1016/j.inoche.2020.108395 ↗
47. Hartono M, Baker AG, Else TR, et al. Photoacoustic polydopamine-indocyanine green (PDA-ICG) nanoprobe for detection of senescent cells. Sci Rep, 2024, 14: 2950610.1038/s41598-024-79667-7 ↗
48. Wu Y, Yuan C, Jia X, et al. Efficient ROS activation by highly stabilized aqueous ICG encapsulated upconversion nanoparticles for tumor cell imaging and therapeutics. Chem Eng J, 2023, 452: 13934310.1016/j.cej.2022.139343 ↗
49. Yan Y, Han R, Hou Y, et al. Bowl-like mesoporous polydopamine with size exclusion for highly selective recognition of endogenous glycopeptides. Talanta, 2021, 233: 12246810.1016/j.talanta.2021.122468 ↗
50. Li X, Liang X, Yang C, et al. Nonlinear amplification of nano bowl surface concavity on the critical response threshold to biosignals. Nat Commun, 2024, 15: 869910.1038/s41467-024-53053-3 ↗
51. Zhang YN, Poon W, Tavares AJ, et al. Nanoparticle-liver interactions: cellular uptake and hepatobiliary elimination. J Control Release, 2016, 240: 332–34810.1016/j.jconrel.2016.01.020 ↗